Sign In
Buy PRQR
$1.72
-0.0600 (-3.37%)
At Close: Jul 31, 2026
ProQR Announces Year End 2025 Operating and Financial Results
07:00am, Thursday, 12'th Mar 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies ba
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference
04:30pm, Tuesday, 03'rd Mar 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
ProQR Announces Planned Changes to Board Composition
08:00am, Monday, 09'th Feb 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of “Moderate Buy” from Brokerages
01:22am, Friday, 16'th Jan 2026
ProQR Therapeutics N.V. (NASDAQ: PRQR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine brokerages that are covering the stock, MarketBeat reports. One in
ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook
08:00am, Thursday, 08'th Jan 2026
Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1 enrollment and dosing in healthy volunteers ongoing with target enga
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Recommendation of “Moderate Buy” from Analysts
01:11am, Monday, 22'nd Dec 2025
Shares of ProQR Therapeutics N.V. (NASDAQ: PRQR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine research firms that are presently covering the firm, Mar
ProQR to Participate in 8th Annual Evercore Healthcare Conference
08:00am, Monday, 01'st Dec 2025
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas
ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates
09:11am, Thursday, 06'th Nov 2025
ProQR (PRQR) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.11 per share a year ago.
ProQR Announces Third Quarter 2025 Operating and Financial Results
07:00am, Thursday, 06'th Nov 2025
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies b
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript
06:46pm, Monday, 03'rd Nov 2025
ProQR Therapeutics N.V. ( PRQR ) Shareholder/Analyst Call November 3, 2025 10:00 AM EST Company Participants Sarah Kiely - Vice President of Investor Relations & Corporate Communications Daniel de Boe
ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
08:00am, Monday, 20'th Oct 2025
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas
ProQR to Participate in Upcoming Investor Conferences in October 2025
08:30am, Monday, 13'th Oct 2025
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas
ProQR Announces Second Quarter 2025 Operating and Financial Results
07:00am, Thursday, 07'th Aug 2025
LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies b
ProQR Announces Upcoming Presentation at RNA Editing Summit
08:00am, Monday, 28'th Jul 2025
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
04:30pm, Thursday, 26'th Jun 2025
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based
